GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GAIA-102 overview

GAIA-102 is under development for the treatment of ovarian cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, pancreatic cancer, rhabdomyosarcoma, undifferentiated sarcoma, Ewing's sarcoma, osteosarcoma, other cartilage sarcoma, nephroblastoma, hepatoblastoma and germ cell neoplasma and neuroblastoma. The drug candidate comprise of highly activated and expanded natural killer cells. It is administered intravenous and intraperitoneal routes of administration.

GAiA BioMedicine overview

GAiA BioMedicine, is a developer of a biopharmaceutical company intended to deliver new therapeutic agents that specializes in cell therapies and immunotherapies. The company is headquartered in Japan.

For a complete picture of GAIA-102’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.